GAVRETO Safety
GAVRETO offers a well-established safety profile
Safety of GAVRETO was evaluated in 138 patients with RET-altered thyroid cancer1*
*Includes 19 patients with RET fusion-positive thyroid cancer.
RET+=rearranged during transfection.
Adverse reactions (≥15%) in RET-altered thyroid cancer patients who received GAVRETO in ARROW1
Adverse Reactions | GAVRETO (N=138)* | |
Grades 1-4 (%) | Grades 3-4 (%) | |
Musculoskeletal | ||
Musculoskeletal pain† | 42 | 0.7‡ |
Gastrointestinal | ||
Constipation | 41 | 0.7‡ |
Diarrhea† | 34 | 5‡ |
Abdominal pain† | 17 | 0.7‡ |
Dry mouth | 17 | 0 |
Stomatitis† | 17 | 0.7‡ |
Nausea | 17 | 0.7‡ |
Vascular | ||
Hypertension | 40 | 21‡ |
General | ||
Fatigue† | 38 | 6‡ |
Edema† | 29 | 0 |
Pyrexia | 22 | 2.2‡ |
Respiratory | ||
Cough† | 27 | 1.4‡ |
Dyspnea† | 22 | 2.2‡ |
Nervous system | ||
Headache† | 24 | 0 |
Peripheral neuropathy† | 20 | 0 |
Dizziness† | 19 | 0.7‡ |
Dysgeusia† | 17 | 0 |
Skin and subcutaneous | ||
Rash† | 24 | 0 |
Metabolism and nutrition | ||
Decreased appetite | 15 | 0 |
*Includes 19 patients with RET fusion-positive thyroid cancer.
†For grouped terms, please refer to the U.S. Prescribing Information (USPI).
‡Only includes a Grade 3 adverse reaction.
Clinically relevant adverse reactions in <15% of patients who received GAVRETO included tumor lysis syndrome and increased creatine phosphokinase.
Dose reductions, interruptions, and discontinuations due to adverse reactions while taking GAVRETO1,2
- 3.6% discontinued due to adverse reactions considered treatment-related by the trial investigator2
- 9% of patients permanently discontinued GAVRETO due to any adverse reaction1
- 44% of patients treated experienced dose reductions due to an adverse reaction1
- 67% of patients treated experienced dosage interruptions due to an adverse reaction1
Select laboratory abnormalities (≥20%) worsening from baseline in patients who received GAVRETO in ARROW1
Laboratory Abnormality§ | GAVRETO (N=138)* | |
Grades 1-4 (%) | Grades 3-4 (%) | |
Chemistry | ||
Decreased calcium (corrected) | 70 | 9 |
Increased aspartate aminotransferase (AST) | 69 | 4.3 |
Increased alanine aminotransferase (ALT) | 43 | 3.6 |
Increased creatinine | 41 | 0 |
Decreased albumin | 41 | 1.5 |
Decreased sodium | 28 | 2.2 |
Decreased phosphate | 28 | 8 |
Decreased magnesium | 27 | 0.7 |
Increased potassium | 26 | 1.4 |
Increased bilirubin | 24 | 1.4 |
Increased alkaline phosphatase | 22 | 1.4 |
Hematology | ||
Decreased lymphocytes | 67 | 27 |
Decreased hemoglobin | 63 | 13 |
Decreased neutrophils | 59 | 16 |
Decreased platelets | 31 | 2.9 |
GAVRETO showed Grades 3-4 AST/ALT elevations of 4.3% and 3.6%.1
*Includes 19 patients with RET fusion-positive thyroid cancer.
§Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 135 to 138 patients.
Other clinically relevant laboratory abnormalities in patients who received GAVRETO included increased phosphate (40%).1
When should I modify dosage?
View the recommended dose reductions for GAVRETO for adverse reactions.
GAV_THR-25011 0525
References:
1. GAVRETO® [Package insert], South San Francisco, CA: Rigel Pharmaceuticals, Inc.
2. GAVRETO: Data on file, Rigel Pharmaceuticals, Inc. June 2024.